The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
HER2-Targeted Therapy Reduces Incidence and Progression of Midlife Mammary Tumors in Female Murine Mammary Tumor Virus huHER2-Transgenic Mice
Open accessAbstract
PURPOSE: This study examined the effectiveness of early and prolonged mu4D5 (the murine form of trastuzumab/Herceptin) treatment in transgenic mice that overexpress human HER2 (huHER2), under the murine mammary tumor virus promoter, as a model of huHER2-overexpressing breast cancer. EXPERIMENTAL DESIGN: Mice were randomly assigned to one of three treatment groups and received i.p. injections from 17 weeks of age until either 52 weeks of age or morbidity. Fourteen mice received 100 mg/kg mu4D5, 14 mice received 100 mg/kg antiherpes simplex virus glycoprotein D control antibody, and 11 mice received a diluent control. RESULTS: High levels of huHER2 expression were detectable in mammary glands of young virgin founder mice. Mammary adenocarcinomas were frequently found in female founders and progeny at an average age of 28 weeks, with some progressing to metastatic disease. The incidence of mammary tumors was significantly reduced, and tumor growth inhibition was observed in mice receiving mu4D5 compared with control mice. In addition, Harderian gland neoplasms, highly associated with overexpression of huHER2 in this transgenic line, were entirely absent in the mu4D5 treatment group, indicating down-regulation of huHER2 in vivo activity. CONCLUSIONS: Early intervention with mu4D5 was of benefit in our transgenic mice at high risk for developing huHER2-overexpressing breast cancer. This study suggests a potential benefit of early treatment with Herceptin in HER2-positive primary breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Consistent with its oncogenic activity, overexpression of wild-type Neu or HER2 under the control of a mammary-specific promoter leads to metastatic mammary tumors in transgenic mice (Andrechek et al., 2000; Finkle et al., 2004).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Finkle et al., 2004
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,269
Manipulating the mouse embryo: A laboratory manual
Hogan, B. L. M., Costantini, F. D., & Lacy, E. (1986) · Cited by 4,460
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Hanahan, D. (1985) · Nature · doi:10.1038/315115a0 · Cited by 1,281
Muller, W., Sinn, E., Pattengale, P., Wallace, R., & Leder, P. (1988) · Cell · doi:10.1016/0092-8674(88)90184-5 · Cited by 1,246
Guy, C. T., Webster, M. A., Schaller, M. D., Parsons, T. J., Cardiff, R. D., & Muller, W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10578 · Cited by 1,193
ErbB2 is essential in the prevention of dilated cardiomyopathy
Crone, S. A., Zhao, Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., Peterson, K. L., Chen, J., Kahn, R., Condorelli, G., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-459 · Cited by 902
Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes
Stewart, T. A., Pattengale, P. K., & Leder, P. (1984) · Cell · doi:10.1016/0092-8674(84)90257-5 · Cited by 892
Cited by
Sorted by citations
Items 101–125 of 125
Monoclonal Antibodies for Cancer Therapy and Prevention
Zhang, H., Samanta, A., Nagai, Y., Tsuchiya, H., Ohtani, T., Cai, Z., Zhu, Z., Liu, J., & Greene, M. I. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00014-2 · Cited by 2
Neuregulin Signaling in the Tumor Microenvironment
Jia, R., Zhao, H., & Wang, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-47189-7_1 · Cited by 1
Veterinary Management of Harderian Gland Tumors in Cancer Rainbow (crainbow) HER2-Positive Mice
Garner, A., Ginzel, J. D., Snyder, J. C., Everitt, J. I., & Landon, C. D. (2022) · Comparative Medicine · doi:10.30802/aalas-cm-22-000061 · Cited by 2
Gedik, M. E., Saatci, Ö., Oberholtzer, N. P., Üner, M., Akbulut, Ö., Çetįn, M., Aras, M., İbiş, K., Çalışkan, B., Banoğlu, E., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.12.557273 · Cited by 2
Integrative and Emerging Models in Antibody Research: A Comprehensive Review
Devasani, J. R., Guntuku, G., sarabu, P., Muthyala, M. K. K., Palla, M. S., & Volety, M. S. (2025) · Antibody Therapeutics · doi:10.1093/abt/tbaf018 · Cited by 2
The basics of in situ hybridization
Nuovo, G. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820653-9.00004-3 · Cited by 1
Understanding acquired resistance to Lapatinib in breast cancer cells
Tseng, J. (2010) · Digital Commons-TMC (Texas Medical Center) · Cited by 1
Mendes, O. R. (2005) · OakTrust (Texas A&M University Libraries)
her2 hyper-activation through the production of carboxy-terminal fragments
Angelini, P. D. (2014) · TDX (Tesis Doctorals en Xarxa)
The role of mTORC2 in mammary morphogenesis and HER2-mediated tumorigenesis
Morrison, M. M. (2015)
Anticancer innovative therapy: Highlights from the ninth annual meeting
Volpari, T., Santis, F. D., Bracken, A. P., Pupa, S. M., Buschbeck, M., Wegner, A., Cosimo, S. D., Lisanti, M. P., Dotti, G., Massaia, M., et al. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2019.12.002
HER2-Positive (HER2 +) Breast Cancer
Dilday, T., & Yeh, E. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00055-4
The Basics of In Situ Hybridization
(2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415944-0.00004-8
Miller, T. W., Forbes, J. T., Shah, C., Wyatt, S. K., Manning, H. C., Olivares, M. G., Sanchez, V. M., Dugger, T. C., Granja, N. D. M., Narasanna, A., et al. (2023) · doi:10.1158/1078-0432.c.6517720
Ali, A. I., Wang, M., von Scheidt, B., Domínguez, P. M., Harrison, A. J., Tantalo, D. G. M., Kang, J., Oliver, A. J., Chan, J. D., Du, X., et al. (2023) · doi:10.1158/1078-0432.c.6530693
Miller, T. W., Forbes, J. T., Shah, C., Wyatt, S. K., Manning, H. C., Olivares, M. G., Sanchez, V. M., Dugger, T. C., Granja, N. D. M., Narasanna, A., et al. (2023) · doi:10.1158/1078-0432.c.6517720.v1
Shah, C., Miller, T. W., Wyatt, S. K., McKinley, E. T., Olivares, M. G., Sanchez, V. M., Nolting, D. D., Buck, J. R., Zhao, P., Ansari, M. S., et al. (2023) · doi:10.1158/1078-0432.c.6517900.v1
Ali, A. I., Wang, M., von Scheidt, B., Domínguez, P. M., Harrison, A. J., Tantalo, D. G. M., Kang, J., Oliver, A. J., Chan, J. D., Du, X., et al. (2023) · doi:10.1158/1078-0432.c.6530693.v1
The role of NEDD9 in HER2-driven breast cancer.
Purazo, M. L. (2023) · doi:10.33915/etd.11996
Development of Highly Sensitive Anti-Mouse HER2 Monoclonal Antibodies for Flow Cytometry
Ouchida, T., Suzuki, H., Tanaka, T., Kaneko, M. K., & Kato, Y. (2023) · International Journal of Translational Medicine · doi:10.3390/ijtm3030022
Goel, P. N., Katsumata, M., Qian, W., Mathur, S., Ji, M., Samanta, A., Grover, P., Sgouros, G., Chang, J. C., & Greene, M. I. (2024) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s490904
Momeny, M. (2015) · The University of Queensland · doi:10.14264/uql.2015.300
Metadata
- Authors
- Finkle, D., Quan, Z. R., Asghari, V., Kloss, J., Ghaboosi, N., Mai, E., Wong, W. L., Hollingshead, P., Schwall, R., Koeppen, H., & Erickson, S.
- Affiliations
- 1Physiology, Departments of
- 2Assay and Automation Technology,
- Molecular Oncology (United States) (US)
- Genentech (US)
- Venue
- Clinical Cancer Research
- Published
- 2004-04-01
- Volume
- 10
- Issue
- 7
- Pages
- 2499-2511
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2166433072
- Cited by
- 125
- References
- 33
- Citations by year
- 2025: 5 · 2024: 4 · 2023: 15 · 2022: 1 · 2021: 6 · 2020: 7 · 2019: 5 · 2018: 2 · 2017: 6 · 2016: 11 · 2015: 7 · 2014: 9 · 2013: 6 · 2012: 4
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Genentech
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- HER2, trastuzumab, HER2-positive breast cancer, early intervention, tumor incidence, tumor progression, metastasis
- MeSH terms
- Trastuzumab, Animals, Antibodies, Monoclonal, Base Sequence, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunohistochemistry, Lung Neoplasms, Mammary Tumor Virus, Mouse, Mice, Transgenic, Models, Genetic, Molecular Sequence Data, Neoplasm Metastasis, Neoplasms, Experimental, Promoter Regions, Genetic, RNA, RNA, Messenger, Time Factors, Down-Regulation, Mammary Neoplasms, Animal, In Situ Hybridization, Fluorescence, Disease Progression, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Transgenes, Reverse Transcriptase Polymerase Chain Reaction, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
